Cohort 2: niraparib and dostarlimab
Twenty-two patients were enrolled in C2 (Fig Median number of cycles was three (range 1–20). The CBR was 31.8% (7/22; 95% CI 16–53) and median clinical benefit duration was 6.8 months (95% CI 3.7–9.5). The ORR was 14% (3/22; 95% CI 3–35), with three patients experiencing a partial response (Fig. 